277 related articles for article (PubMed ID: 25033808)
1. Inhibitors of K-Ras plasma membrane localization.
Cho KJ; van der Hoeven D; Hancock JF
Enzymes; 2013; 33 Pt A():249-65. PubMed ID: 25033808
[TBL] [Abstract][Full Text] [Related]
2. Fendiline inhibits K-Ras plasma membrane localization and blocks K-Ras signal transmission.
van der Hoeven D; Cho KJ; Ma X; Chigurupati S; Parton RG; Hancock JF
Mol Cell Biol; 2013 Jan; 33(2):237-51. PubMed ID: 23129805
[TBL] [Abstract][Full Text] [Related]
3. Recent progress in developing small molecule inhibitors designed to interfere with ras membrane association: toward inhibiting K-Ras and N-Ras functions.
Tamanoi F; Lu J
Enzymes; 2013; 34 Pt. B():181-200. PubMed ID: 25034105
[TBL] [Abstract][Full Text] [Related]
4. Improving Prospects for Targeting RAS.
Singh H; Longo DL; Chabner BA
J Clin Oncol; 2015 Nov; 33(31):3650-9. PubMed ID: 26371146
[TBL] [Abstract][Full Text] [Related]
5. RAS Function in cancer cells: translating membrane biology and biochemistry into new therapeutics.
Kattan WE; Hancock JF
Biochem J; 2020 Aug; 477(15):2893-2919. PubMed ID: 32797215
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic modulation of k-ras signaling in colorectal cancer.
Krens LL; Baas JM; Gelderblom H; Guchelaar HJ
Drug Discov Today; 2010 Jul; 15(13-14):502-16. PubMed ID: 20594936
[TBL] [Abstract][Full Text] [Related]
7. Phenotypic Screening Identifies Protein Synthesis Inhibitors as H-Ras-Nanocluster-Increasing Tumor Growth Inducers.
Najumudeen AK; Posada IM; Lectez B; Zhou Y; Landor SK; Fallarero A; Vuorela P; Hancock J; Abankwa D
Biochemistry; 2015 Dec; 54(49):7212-21. PubMed ID: 26568031
[TBL] [Abstract][Full Text] [Related]
8. Another surprise from Metformin: novel mechanism of action via K-Ras influences endometrial cancer response to therapy.
Iglesias DA; Yates MS; van der Hoeven D; Rodkey TL; Zhang Q; Co NN; Burzawa J; Chigurupati S; Celestino J; Bowser J; Broaddus R; Hancock JF; Schmandt R; Lu KH
Mol Cancer Ther; 2013 Dec; 12(12):2847-56. PubMed ID: 24077915
[TBL] [Abstract][Full Text] [Related]
9. Wild-type H- and N-Ras promote mutant K-Ras-driven tumorigenesis by modulating the DNA damage response.
Grabocka E; Pylayeva-Gupta Y; Jones MJ; Lubkov V; Yemanaberhan E; Taylor L; Jeng HH; Bar-Sagi D
Cancer Cell; 2014 Feb; 25(2):243-56. PubMed ID: 24525237
[TBL] [Abstract][Full Text] [Related]
10. Staurosporines disrupt phosphatidylserine trafficking and mislocalize Ras proteins.
Cho KJ; Park JH; Piggott AM; Salim AA; Gorfe AA; Parton RG; Capon RJ; Lacey E; Hancock JF
J Biol Chem; 2012 Dec; 287(52):43573-84. PubMed ID: 23124205
[TBL] [Abstract][Full Text] [Related]
11. Ras and exosome signaling.
Sexton RE; Mpilla G; Kim S; Philip PA; Azmi AS
Semin Cancer Biol; 2019 Feb; 54():131-137. PubMed ID: 30769101
[TBL] [Abstract][Full Text] [Related]
12. Targeting RAS Membrane Association: Back to the Future for Anti-RAS Drug Discovery?
Cox AD; Der CJ; Philips MR
Clin Cancer Res; 2015 Apr; 21(8):1819-27. PubMed ID: 25878363
[TBL] [Abstract][Full Text] [Related]
13. Recent Advances in Developing K-Ras Plasma Membrane Localization Inhibitors.
Ye N; Xu Q; Li W; Wang P; Zhou J
Curr Top Med Chem; 2019; 19(23):2114-2127. PubMed ID: 31475899
[TBL] [Abstract][Full Text] [Related]
14. Scaffold repurposing of fendiline: Identification of potent KRAS plasma membrane localization inhibitors.
Wang P; van der Hoeven D; Ye N; Chen H; Liu Z; Ma X; Montufar-Solis D; Rehl KM; Cho KJ; Thapa S; Chen W; van der Hoeven R; Frost JA; Hancock JF; Zhou J
Eur J Med Chem; 2021 May; 217():113381. PubMed ID: 33756124
[TBL] [Abstract][Full Text] [Related]
15. Targeting the K-Ras/PDEδ protein-protein interaction: the solution for Ras-driven cancers or just another therapeutic mirage?
Frett B; Wang Y; Li HY
ChemMedChem; 2013 Oct; 8(10):1620-2. PubMed ID: 23939923
[TBL] [Abstract][Full Text] [Related]
16. Isolation of a chemical inhibitor against K-Ras-induced p53 suppression through natural compound screening.
Lee SJ; Jung YS; Lee SH; Chung HY; Park BJ
Int J Oncol; 2009 Jun; 34(6):1637-43. PubMed ID: 19424582
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of RAS: proven and potential vulnerabilities.
Zuberi M; Khan I; O'Bryan JP
Biochem Soc Trans; 2020 Oct; 48(5):1831-1841. PubMed ID: 32869838
[TBL] [Abstract][Full Text] [Related]
18. RAS: target for cancer therapy.
Saxena N; Lahiri SS; Hambarde S; Tripathi RP
Cancer Invest; 2008 Nov; 26(9):948-55. PubMed ID: 18798058
[TBL] [Abstract][Full Text] [Related]
19. Bisubstrate inhibitors of farnesyltransferase: a novel class of specific inhibitors of ras transformed cells.
Manne V; Yan N; Carboni JM; Tuomari AV; Ricca CS; Brown JG; Andahazy ML; Schmidt RJ; Patel D; Zahler R
Oncogene; 1995 May; 10(9):1763-79. PubMed ID: 7753553
[TBL] [Abstract][Full Text] [Related]
20. Components of the phosphatidylserine endoplasmic reticulum to plasma membrane transport mechanism as targets for KRAS inhibition in pancreatic cancer.
Kattan WE; Liu J; Montufar-Solis D; Liang H; Brahmendra Barathi B; van der Hoeven R; Zhou Y; Hancock JF
Proc Natl Acad Sci U S A; 2021 Dec; 118(51):. PubMed ID: 34903667
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]